Equities research analysts predict that Natera Inc (NASDAQ:NTRA) will announce earnings per share of ($0.60) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Natera’s earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.72). Natera reported earnings of ($0.51) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 17.6%. The company is expected to report its next earnings results on Tuesday, March 10th.
On average, analysts expect that Natera will report full year earnings of ($1.95) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($1.83). For the next year, analysts expect that the company will report earnings of ($1.87) per share, with EPS estimates ranging from ($2.84) to ($1.11). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Natera.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.20. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The company had revenue of $77.90 million during the quarter, compared to the consensus estimate of $73.97 million. During the same period in the prior year, the firm earned ($0.49) earnings per share. Natera’s revenue was up 19.3% on a year-over-year basis.
NTRA stock traded up $1.52 during trading on Monday, reaching $39.83. The company had a trading volume of 422,300 shares, compared to its average volume of 742,237. The business has a 50 day moving average of $36.87 and a 200 day moving average of $29.24. Natera has a 52 week low of $11.08 and a 52 week high of $40.92. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.35 and a quick ratio of 2.42. The company has a market cap of $3.06 billion, a P/E ratio of -18.53 and a beta of 1.45.
In other Natera news, CFO Michael Burkes Brophy sold 2,859 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $38.25, for a total value of $109,356.75. Following the transaction, the chief financial officer now directly owns 16,630 shares in the company, valued at $636,097.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,155 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total transaction of $34,072.50. Following the completion of the transaction, the chief executive officer now owns 4,525 shares in the company, valued at $133,487.50. The disclosure for this sale can be found here. Insiders sold 64,557 shares of company stock worth $2,241,958 over the last quarter. Insiders own 9.29% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Tower Research Capital LLC TRC bought a new stake in shares of Natera during the 3rd quarter valued at $36,000. Focused Wealth Management Inc bought a new stake in shares of Natera during the 2nd quarter valued at $83,000. US Bancorp DE raised its position in shares of Natera by 575.2% during the 2nd quarter. US Bancorp DE now owns 3,099 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 2,640 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Natera by 23.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the medical research company’s stock valued at $93,000 after purchasing an additional 537 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of Natera during the 2nd quarter valued at $129,000. Institutional investors and hedge funds own 95.53% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: Capital gains and your 401(k) or IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.